Andrew S. Chi

Clinical Cancer Research Senior Editor

Dr. Andrew S. Chi, an accomplished researcher and physician, joined Clinical Cancer Research (CCR) as a senior editor in 2017. Dr. Chi currently works as the Senior Medical Director at Mirati Therapeutics.

His research encompasses the neoantigen biology of cancer and neoantigen-directed immunotherapy, the identification of novel therapeutic targets and biomarkers in glioma, and metabolic targeting of glioma genetic subtypes. Dr. Chi, with his collaborators and team members, has made discoveries that have revealed novel therapeutic strategies and diagnostic biomarkers, including the identification of the cell surface Notch receptor DLL3 as a therapeutic target in IDH mutant glioma, the identification of the T2-FLAIR mismatch sign as a 100% specific MRI biomarker for IDH mutant astrocytomas, and the hypersensitivity of IDH mutant and MYC/MYCN amplified cancers to inhibitors of NAD+ biosynthesis.

Dr. Chi has been an AACR member since 2017 and has participated in various AACR meetings and conferences. In 2010, he was an invited speaker at the AACR Special Conference on Cancer Epigenetics in San Juan, Puerto Rico, and in 2016 he was selected to give an oral presentation at the AACR annual meeting in New Orleans. Additionally, Dr. Chi has been an invited discussant in the Central Nervous System Tumors Session at the two most recent ASCO annual meetings. Prior to his appointment as a senior editor for CCR, Dr. Chi served as an ad hoc reviewer for CCR from 2013-2017 and has served as an ad hoc reviewer for AACR’s flagship publication, Cancer Research, since 2014.

Dr. Chi graduated with a BA from Boston University, and then went on to gain a MD/PhD in Biochemistry and Molecular Biology from Chicago Medical School. Upon graduation, he served as the Chief Resident in Neurology at MGH/BWH/Harvard Medical School, and then completed a Neuro-oncology fellowship at MGH/DFCI/Harvard Medical School. In 2010, he won an Early Cancer Researcher Award from the Ben and Catherine Ivy Foundation, and in 2018 he was honored as one of the 45 faces of the American Brain Tumor Association for his contributions to the brain tumor field. Prior to assuming his current position at Mirati, Dr. Chi was a principal investigator for numerous multi-institutional glioma clinical trials and served as the director of Neuro-oncology and co-director of the Brain Tumor Center at NYU.

• PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors
  K. Tateishi…D.P. Cahill. Clinical Cancer Research April 2019.
• Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma
  M. Spino…A.S. Chi. Clinical Cancer Research February 2019.
• Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma
  J.O. Blakeley…X. Ye. Clinical Cancer Research January 2019.
• T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project
  S.H. Patel…R. Jain. Clinical Cancer Research October 2017.
• The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD⁺ Depletion–Mediated Cytotoxicity
  K. Tateishi…D.P. Cahill. Cancer Research August 2017.